BIOKIN (688506.SH) receives CSRC supplementary filing requirements for Hong Kong listing, queried on indirect shareholding, overseas subsidiary compliance and listing necessity
NewTimeSpace News: On November 9, 2026, the CSRC disclosed on November 6 its supplementary filing requirements for overseas listings. Between November 2 and November 6, 2026, the International Cooperation Department issued supplementary filing requirements to three companies, among them Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH).
For Biokin, the CSRC requires the company to further explain its actual controller's indirect shareholding, as well as the specific implementation of regulatory procedures such as overseas investment and foreign exchange registration involving its overseas subsidiaries, and to issue a conclusive opinion on compliance. The company is also required to explain in detail, in light of the use of its A-share fundraising proceeds, the necessity of its Hong Kong listing.
The CSRC further requires Biokin to explain in detail the reasons for its previously unsuccessful listing attempts and the measures taken for the current offering. All the above matters must be verified by lawyers, who shall issue clear legal opinions.
- Sichuan Biokin Pharmaceutical Files for Hong Kong IPO: Yizekang Becomes World's First Approved Bispecific ADC with 15 Clinical-Stage Pipeline Candidates
- iShares MSCI Taiwan (03074.HK) rises 4.42%, 10th stabilisation move
- iShares India (02836.HK) jumps 5.37%, India Oct manufacturing PMI 54.7
- EHOLY receives CSRC supplementary filing requirements for Hong Kong listing, queried on shareholding entrustment, new shareholder pricing, industry competition and full circulation share defects
- BOQIAN NEW MATERIALS (605376.SH) receives CSRC supplementary filing requirements for Hong Kong listing, queried on energy emissions, leasing qualifications, listing necessity and pledge risks
